Literature DB >> 25900135

Influenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineage.

Carolien E van de Sandt1, YingYing Dou1, Stella E Vogelzang-van Trierum1, Kim B Westgeest1, Mark R Pronk1, Albert D M E Osterhaus1,2, Ron A M Fouchier1, Guus F Rimmelzwaan2,1, Marine L B Hillaire1.   

Abstract

Influenza B viruses fall in two antigenically distinct lineages (B/Victoria/2/1987 and B/Yamagata/16/1988 lineage) that co-circulate with influenza A viruses of the H3N2 and H1N1 subtypes during seasonal epidemics. Infections with influenza B viruses contribute considerably to morbidity and mortality in the human population. Influenza B virus neutralizing antibodies, elicited by natural infections or vaccination, poorly cross-react with viruses of the opposing influenza B lineage. Therefore, there is an increased interest in identifying other correlates of protection which could aid the development of broadly protective vaccines. blast analysis revealed high sequence identity of all viral proteins. With two online epitope prediction algorithms, putative conserved epitopes relevant for study subjects used in the present study were predicted. The cross-reactivity of influenza B virus-specific polyclonal CD8+ cytotoxic T-lymphocyte (CTL) populations obtained from HLA-typed healthy study subjects, with intra-lineage drift variants and viruses of the opposing lineage, was determined by assessing their in vitro IFN-γ response and lytic activity. Here, we show for the first time, to the best of our knowledge, that CTLs directed to viruses of the B/Victoria/2/1987 lineage cross-react with viruses of the B/Yamagata/16/1988 lineage and vice versa.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25900135      PMCID: PMC4681061          DOI: 10.1099/vir.0.000156

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  79 in total

1.  Reconstitution by MHC-restricted peptides of HLA-A2 heavy chain with beta 2-microglobulin, in vitro.

Authors:  M L Silver; K C Parker; D C Wiley
Journal:  Nature       Date:  1991-04-18       Impact factor: 49.962

2.  Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines.

Authors:  Xiao-Song He; Tyson H Holmes; Caiqiu Zhang; Kutubuddin Mahmood; George W Kemble; David B Lewis; Cornelia L Dekker; Harry B Greenberg; Ann M Arvin
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

3.  Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature.

Authors:  Suzanne L Epstein
Journal:  J Infect Dis       Date:  2005-11-21       Impact factor: 5.226

4.  Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity.

Authors:  Robert B Belshe; Kathleen Coelingh; Christopher S Ambrose; Jennifer C Woo; Xionghua Wu
Journal:  Vaccine       Date:  2009-12-08       Impact factor: 3.641

5.  Highly conserved protective epitopes on influenza B viruses.

Authors:  Cyrille Dreyfus; Nick S Laursen; Ted Kwaks; David Zuijdgeest; Reza Khayat; Damian C Ekiert; Jeong Hyun Lee; Zoltan Metlagel; Miriam V Bujny; Mandy Jongeneelen; Remko van der Vlugt; Mohammed Lamrani; Hans J W M Korse; Eric Geelen; Özcan Sahin; Martijn Sieuwerts; Just P J Brakenhoff; Ronald Vogels; Olive T W Li; Leo L M Poon; Malik Peiris; Wouter Koudstaal; Andrew B Ward; Ian A Wilson; Jaap Goudsmit; Robert H E Friesen
Journal:  Science       Date:  2012-08-09       Impact factor: 47.728

6.  Comparison of experimental fine-mapping to in silico prediction results of HIV-1 epitopes reveals ongoing need for mapping experiments.

Authors:  Julia Roider; Tim Meissner; Franziska Kraut; Thomas Vollbrecht; Renate Stirner; Johannes R Bogner; Rika Draenert
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

7.  The effect of a previous attack of A1 influenza on susceptibility to A2 virus during the 1957 outbreak.

Authors:  A N SLEPUSHKIN
Journal:  Bull World Health Organ       Date:  1959       Impact factor: 9.408

8.  Mortality associated with influenza and respiratory syncytial virus in the United States.

Authors:  William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Nancy Cox; Larry J Anderson; Keiji Fukuda
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

9.  Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro.

Authors:  G F Rimmelzwaan; M Baars; E C Claas; A D Osterhaus
Journal:  J Virol Methods       Date:  1998-09       Impact factor: 2.014

10.  Human infection with a novel avian-origin influenza A (H7N9) virus.

Authors:  Rongbao Gao; Bin Cao; Yunwen Hu; Zijian Feng; Dayan Wang; Wanfu Hu; Jian Chen; Zhijun Jie; Haibo Qiu; Ke Xu; Xuewei Xu; Hongzhou Lu; Wenfei Zhu; Zhancheng Gao; Nijuan Xiang; Yinzhong Shen; Zebao He; Yong Gu; Zhiyong Zhang; Yi Yang; Xiang Zhao; Lei Zhou; Xiaodan Li; Shumei Zou; Ye Zhang; Xiyan Li; Lei Yang; Junfeng Guo; Jie Dong; Qun Li; Libo Dong; Yun Zhu; Tian Bai; Shiwen Wang; Pei Hao; Weizhong Yang; Yanping Zhang; Jun Han; Hongjie Yu; Dexin Li; George F Gao; Guizhen Wu; Yu Wang; Zhenghong Yuan; Yuelong Shu
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

View more
  16 in total

1.  Variation at Extra-epitopic Amino Acid Residues Influences Suppression of Influenza Virus Replication by M158-66 Epitope-Specific CD8+ T Lymphocytes.

Authors:  Carolien E van de Sandt; Mark R Pronk; Carel A van Baalen; Ron A M Fouchier; Guus F Rimmelzwaan
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

2.  Single-replication BM2SR vaccine provides sterilizing immunity and cross-lineage influenza B virus protection in mice.

Authors:  Michael J Moser; Yasuko Hatta; Claudia Gabaglia; Adriana Sanchez; Peter Dias; Sally Sarawar; Yoshihiro Kawaoka; Masato Hatta; Gabriele Neumann; Pamuk Bilsel
Journal:  Vaccine       Date:  2019-07-04       Impact factor: 3.641

3.  Evidence for Viral Interference and Cross-reactive Protective Immunity Between Influenza B Virus Lineages.

Authors:  Karen L Laurie; William Horman; Louise A Carolan; Kok Fei Chan; Daniel Layton; Andrew Bean; Dhanasekaran Vijaykrishna; Patrick C Reading; James M McCaw; Ian G Barr
Journal:  J Infect Dis       Date:  2018-01-30       Impact factor: 5.226

Review 4.  Influenza B: Prospects for the Development of Cross-Protective Vaccines.

Authors:  Liudmila M Tsybalova; Liudmila A Stepanova; Edward S Ramsay; Andrey V Vasin
Journal:  Viruses       Date:  2022-06-17       Impact factor: 5.818

Review 5.  Innate and adaptive T cells in influenza disease.

Authors:  Simone Nüssing; Sneha Sant; Marios Koutsakos; Kanta Subbarao; Thi H O Nguyen; Katherine Kedzierska
Journal:  Front Med       Date:  2018-01-20       Impact factor: 9.927

6.  Multiple Influenza Virus Infections in 4 Consecutive Epidemiological Seasons: A Retrospective Study in Children and Adolescents.

Authors:  Johannes Möst; Monika Redlberger-Fritz; Günter Weiss
Journal:  Open Forum Infect Dis       Date:  2019-04-23       Impact factor: 3.835

7.  Nucleoprotein vaccine induces cross-protective cytotoxic T lymphocytes against both lineages of influenza B virus.

Authors:  So-Young Lee; Jung-Ok Kang; Jun Chang
Journal:  Clin Exp Vaccine Res       Date:  2019-01-31

8.  Trivalent and quadrivalent influenza vaccination effectiveness in Australia and South Africa: results from a modelling study.

Authors:  George J Milne; Nilimesh Halder; Joel K Kelso; Ian G Barr; Jocelyn Moyes; Kathleen Kahn; Rhian Twine; Cheryl Cohen
Journal:  Influenza Other Respir Viruses       Date:  2016-02-08       Impact factor: 4.380

9.  Cross-Protective Efficacy of Monovalent Live Influenza B Vaccines against Genetically Different Lineages of B/Victoria and B/Yamagata in Ferrets.

Authors:  Irina Kiseleva; Elena Krutikova; Ekaterina Stepanova; Svetlana Donina; Maria Pisareva; Vera Krivitskaya; Andrey Rekstin; Erin Grace Sparrow; Guido Torelli; Larisa Rudenko
Journal:  Biomed Res Int       Date:  2018-08-30       Impact factor: 3.411

10.  Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model.

Authors:  Larisa Rudenko; Irina Kiseleva; Elena Krutikova; Ekaterina Stepanova; Andrey Rekstin; Svetlana Donina; Maria Pisareva; Elena Grigorieva; Kirill Kryshen; Arman Muzhikyan; Marina Makarova; Erin Grace Sparrow; Guido Torelli; Marie-Paule Kieny
Journal:  PLoS One       Date:  2018-12-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.